如果您要报告不良事件或产品投诉,请拨打礼来客户服务中心热线400-828-2059(手机),800-828-2059(座机)
返回唯择®（阿贝西利片）
回复：
治疗依从性定义
早期乳腺癌
monarchE 中的依从性和剂量强度总结在monarchE 中的阿贝西利依从性和剂量强度。
方法 |
monarchE |
推荐的阿贝西利剂量 |
150 mg 每日两次 |
剂量依从性（中位数） |
98% |
相对剂量强度（中位数） |
85% |
总体而言，在monarchE试验中，阿贝西利组因不良事件停药的比例为 18.5%（ n=515）。3 与最近的分析（27 个月的随访）相比，在总生存期期中分析2（42.0 个月的中位随访）中没有发现因 AE 导致的额外停药。4
在总生存期期中分析 3 中，中位随访时间为 54.0 个月，100% 的患者停止阿贝西利治疗至少一年，没有出现新的安全问题。5
上次审阅日期：2024年2月28日
参考文献
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Johnston SRD, Harbeck N, Hegg R, et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. https://doi.org/10.1200/JCO.20.02514
3Rugo HS, O’Shaughnessy J, Boyle F, et al; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616-627. https://doi.org/10.1016/j.annonc.2022.03.006
4Johnston SRD, Toi M, O'Shaughnessy J, et al; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77-90. https://doi.org/10.1016/S1470-2045(22)00694-5
5Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42(9):987-993. https://doi.org/10.1200/jco.23.01994
